Investigational^↗Metabolic^↗

Cagrilintide^↗

Related names in cited records: AM833^↗

A long-acting amylin analogue under study. This profile cites a recruiting ClinicalTrials.gov record.^↗

Citation markers ↗ open the public records supporting the adjacent statements.

Profile update · July 27, 2026

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change. ¹

This version supersedes public version 1.

Evidence summary

What the cited records say

ClinicalTrials.gov lists a Novo Nordisk pediatric study as recruiting, updated July 17, 2026.^↗

This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.

Cited context

Dated source history

July 17, 2026
Clinical trials
Cagrilintide pediatric study record updated^↗
ClinicalTrials.gov lists a recruiting Cagrilintide study sponsored by Novo Nordisk A/S.^↗